Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CLDX's Cash to Debt is ranked higher than
99% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. CLDX: No Debt )
CLDX' s 10-Year Cash to Debt Range
Min: 2.73   Max: No Debt
Current: No Debt

Equity to Asset 0.92
CLDX's Equity to Asset is ranked higher than
96% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. CLDX: 0.92 )
CLDX' s 10-Year Equity to Asset Range
Min: -0.12   Max: 0.92
Current: 0.92

-0.12
0.92
F-Score: 4
Z-Score: 26.75
M-Score: 22.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1981.08
CLDX's Operating margin (%) is ranked lower than
53% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. CLDX: -1981.08 )
CLDX' s 10-Year Operating margin (%) Range
Min: -2090.66   Max: -13.79
Current: -1981.08

-2090.66
-13.79
Net-margin (%) -1983.70
CLDX's Net-margin (%) is ranked lower than
52% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. CLDX: -1983.70 )
CLDX' s 10-Year Net-margin (%) Range
Min: -2880.08   Max: -5.41
Current: -1983.7

-2880.08
-5.41
ROE (%) -25.50
CLDX's ROE (%) is ranked higher than
57% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. CLDX: -25.50 )
CLDX' s 10-Year ROE (%) Range
Min: -825.31   Max: -3.37
Current: -25.5

-825.31
-3.37
ROA (%) -23.50
CLDX's ROA (%) is ranked higher than
56% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. CLDX: -23.50 )
CLDX' s 10-Year ROA (%) Range
Min: -228.7   Max: -2.3
Current: -23.5

-228.7
-2.3
ROC (Joel Greenblatt) (%) -816.62
CLDX's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. CLDX: -816.62 )
CLDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2485.93   Max: -59.59
Current: -816.62

-2485.93
-59.59
Revenue Growth (%) -67.60
CLDX's Revenue Growth (%) is ranked higher than
51% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. CLDX: -67.60 )
CLDX' s 10-Year Revenue Growth (%) Range
Min: -67.6   Max: 105.3
Current: -67.6

-67.6
105.3
EPS Growth (%) 133.60
CLDX's EPS Growth (%) is ranked higher than
99% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. CLDX: 133.60 )
CLDX' s 10-Year EPS Growth (%) Range
Min: -64.6   Max: 133.6
Current: 133.6

-64.6
133.6
» CLDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CLDX Guru Trades in Q1 2013

Jim Simons 262,914 sh (+209.72%)
Steven Cohen 3,930,709 sh (+45.58%)
Chuck Royce 300,000 sh (unchged)
Murray Stahl 26,294 sh (unchged)
Jean-Marie Eveillard 1,230,021 sh (-16.36%)
» More
Q2 2013

CLDX Guru Trades in Q2 2013

Chuck Royce 400,000 sh (+33.33%)
Steven Cohen 4,000,000 sh (+1.76%)
Murray Stahl 26,294 sh (unchged)
Jim Simons Sold Out
Jean-Marie Eveillard 665,560 sh (-45.89%)
» More
Q3 2013

CLDX Guru Trades in Q3 2013

Andreas Halvorsen 672,513 sh (New)
Murray Stahl 26,335 sh (+0.16%)
Jean-Marie Eveillard 550,000 sh (-17.36%)
Chuck Royce 273,000 sh (-31.75%)
Steven Cohen 1,489,700 sh (-62.76%)
» More
Q4 2013

CLDX Guru Trades in Q4 2013

Columbia Wanger 1,671,000 sh (New)
Steven Cohen 3,506,488 sh (+135.38%)
Murray Stahl 26,335 sh (unchged)
Andreas Halvorsen Sold Out
Chuck Royce Sold Out
Jean-Marie Eveillard 135,000 sh (-75.45%)
» More
» Details

Insider Trades

Latest Guru Trades with CLDX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-12-31 Reduce -75.45%0.04%$21.51 - $36.71 $ 14.69-42%135000
Jean-Marie Eveillard 2013-06-30 Reduce -45.89%0.02%$11.01 - $16.09 $ 14.6912%665560
George Soros 2012-06-30 Sold Out 0.06%$3.9 - $5.26 $ 14.69235%0
Jean-Marie Eveillard 2012-06-30 Add 260.87%0.02%$3.9 - $5.26 $ 14.69235%1660000
George Soros 2012-03-31 New Buy0.06%$2.77 - $5.46 $ 14.69267%803200
Jean-Marie Eveillard 2012-03-31 Add 360%0.01%$2.77 - $5.46 $ 14.69267%460000
Jean-Marie Eveillard 2011-12-31 Reduce -71.43%$2.11 - $3.21 $ 14.69444%100000
Jean-Marie Eveillard 2011-06-30 New Buy0.01%$3.03 - $4.46 $ 14.69292%350000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Celldex Therapeutics, Inc.

CLDX up 223%, Cohen Gains Big
With new drugs for brain cancer and breast cancer treatment nearing the end of clinical trials, Celldex Therapeutics Inc. (CLDX) is up 223% over the last 12 months. Read more...

Ratios

vs
industry
vs
history
P/B 4.10
CLDX's P/B is ranked higher than
51% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. CLDX: 4.10 )
CLDX' s 10-Year P/B Range
Min: 1.25   Max: 50.74
Current: 4.1

1.25
50.74
P/S 279.00
CLDX's P/S is ranked lower than
91% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. CLDX: 279.00 )
CLDX' s 10-Year P/S Range
Min: 1.68   Max: 631.2
Current: 279

1.68
631.2
EV-to-EBIT 47.60
CLDX's EV-to-EBIT is ranked lower than
70% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. CLDX: 47.60 )
CLDX' s 10-Year EV-to-EBIT Range
Min: 3.5   Max: 4.6
Current: 47.6

3.5
4.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.80
CLDX's Price/Net Cash is ranked higher than
77% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. CLDX: 4.80 )
CLDX' s 10-Year Price/Net Cash Range
Min: 3.21   Max: 21.2
Current: 4.8

3.21
21.2
Price/Net Current Asset Value 4.80
CLDX's Price/Net Current Asset Value is ranked higher than
82% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. CLDX: 4.80 )
CLDX' s 10-Year Price/Net Current Asset Value Range
Min: 3.12   Max: 21.2
Current: 4.8

3.12
21.2
Price/Tangible Book 4.50
CLDX's Price/Tangible Book is ranked higher than
59% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. CLDX: 4.50 )
CLDX' s 10-Year Price/Tangible Book Range
Min: 2.26   Max: 9.75
Current: 4.5

2.26
9.75
Price/Median PS Value 12.80
CLDX's Price/Median PS Value is ranked lower than
80% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. CLDX: 12.80 )
CLDX' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 21.05
Current: 12.8

0.12
21.05
Forward Rate of Return (Yacktman) -4.05
CLDX's Forward Rate of Return (Yacktman) is ranked higher than
66% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. CLDX: -4.05 )
CLDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -48.4   Max: -46.2
Current: -4.05

-48.4
-46.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TCE1.Germany
Celldex Therapeutics, Inc., is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Its drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine that targets the tumor-specific molecule, epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and can directly contribute to cancer cell growth. Its other drug candidates include CDX-011 and CDX-1127. CDX-011 is an antibody-drug conjugate (ADC) that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically targets glycoprotein NMB (GPNMB) that is expressed in a variety of human cancers including breast cancer. In December 2011, it completed enrollment of EMERGE, a randomized Phase 2b study of CDX-011 in patients with heavily pre-treated, advanced, GPNMB-positive breast cancer. It has additional clinical and preclinical programs, including CDX-1401, an APC Targeting Technology program, CDX-301, an immune cell mobilizing agent and dendritic cell growth factor and CDX-1135, a molecule that inhibits a part of the immune system called the complement system. The Company's products are derived from a broad set of complementary technologies which have the ability to utilize the human immune system and enable the creation of therapeutic agents. It is using these technologies to develop targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that prevent or treat cancer and other diseases that modify undesirable activity by the body's own proteins or cells. A number of its immunotherapeutic and antibody-drug conjugate drug candidates are in various stages of clinical trials. The Company faces competition from pharmaceutical and biotechnology companies both in the United States and abroad. In the United States, vaccines and immunotherapeutics for human use are subject to The Food and Drug Administration (FDA) approval as 'biologics' under the Public Health Service Act and 'drugs' under the Federal Food, Drug and Cosmetic Act.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide